JWH-019
 |
|
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
|
|
| CAS Number | 209414-08-4  |
| ChemSpider | 24598813 |
| Chemical and physical data | |
| Formula | C25H25NO |
| Molar mass | 355.471 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (verify) | |
JWH-019 is an analgesic chemical from the naphthoylindole family that acts as a cannabinoid agonist at both the CB1 and CB2 receptors. It is the N1-hexyl homologue of the more common synthetic cannabinoid compound JWH-018. Unlike the butyl homologue JWH-073, which is several times weaker than JWH-018, the hexyl homologue is only slightly less potent, although extending the chain one carbon longer to the heptyl homologue JWH-020 results in dramatic loss of activity. These results show that the optimum side chain length for CB1 binding in the naphthoylindole series is the five-carbon pentyl chain, shorter than in the classical cannabinoids where a seven-carbon heptyl chain produces the most potent compounds. This difference is thought to reflect a slightly different binding conformation adopted by the naphthoylindole compounds as compared to the classical cannabinoids, and may be useful in characterising the active site of the CB1 and CB2 receptors.[2][3][4]
Legal Status[edit]
China[edit]
As of October 2015 JWH-019 is a controlled substance in China.[5]
Poland[edit]
In Poland, JWH-019 is I-N (Poland)[1]
Sweden[edit]
JWH-019 is illegal in Sweden
UK[edit]
JWH-019 is Class B in the United Kingdom.
USA[edit]
JWH-019 is a C-I substance, controlled federally in the United States, and it is not intended for human consumption.
JWH-019 is illegal in Virginia.[6]
See also[edit]
References[edit]
- ^ a b = WDU20111050614 "Ustawa z dnia 15 kwietnia 2011 r. o zmianie ustawy o przeciwdziałaniu narkomanii ( Dz.U. 2011 nr 105 poz. 614 )" Check
|url=value (help). Internetowy System Aktów Prawnych. Retrieved 12 June 2011. - ^ Aung MM, et al. (August 2000). "Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding". Drug and Alcohol Dependence. 60 (2): 133–40. doi:10.1016/S0376-8716(99)00152-0. PMID 10940540.
- ^ Poso A, Huffman JW (January 2008). "Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands". British Journal of Pharmacology. 153 (2): 335–46. doi:10.1038/sj.bjp.0707567. PMC 2219524
. PMID 17982473. - ^ Ashton JC, Wright JL, McPartland JM, Tyndall JD (2008). "Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists". Current Medicinal Chemistry. 15 (14): 1428–43. doi:10.2174/092986708784567716. PMID 18537620.
- ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
- ^ http://crimlaw.blogspot.com/2011/04/no-more-synthetic-cannabinoid.html
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
